José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide

T. Wenzel

DOI: https://doi.org/10.1007/s00216-015-9062-y

2015-10-05

Analytical and Bioanalytical Chemistry

Abstract:

What problem does this paper attempt to address?

Emerging drugs for the treatment of vitiligo

Priyanka Karagaiah,Yan Valle,Julia Sigova,Nicola Zerbinati,Petar Vojvodic,Davinder Parsad,Robert A. Schwartz,Stephan Grabbe,Mohamad Goldust,Torello Lotti

DOI: https://doi.org/10.1080/14728214.2020.1712358

2020-01-02

Expert Opinion on Emerging Drugs

Abstract:Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treatment in current research, followed by antioxidant mechanisms and repigmenting mechanisms. Topical immunosuppressants may be an alternative to steroids in localized vitiligo. Newer repigmenting agents like basic fibroblast growth factors, afamelanotide have been included and a special emphasis is laid on the upcoming targeted immunotherapy.Expert opinion: The treatment of vitiligo needs to be multimodal with emphasis on targeting different limbs of the pathogenesis. Topical and oral JAK inhibitors are the most promising new class of drugs currently available for treating vitiligo and acts best in conjunction with NB-UVB.

pharmacology & pharmacy
Vitiligo: advances in pathophysiology research and treatment development

Zhussipbek Mukhatayev,I. Caroline Le Poole

DOI: https://doi.org/10.1016/j.molmed.2024.04.009

2024-05-06

Trends in Molecular Medicine

Abstract:The autoimmune condition vitiligo, characterized by skin depigmentation, presents challenges for effective treatment design, with Janus kinase (JAK) inhibitors and other repurposed drugs offering a promising strategy for symptom management. This review explores advantages and shortcomings of current therapies, while presenting the urgent need for further innovative approaches. We emphasize the growing understanding of autoimmune involvement in vitiligo, highlighting several novel treatment avenues including relieving melanocyte stress, preventing dendritic cell activation, halting T cell migration, and suppressing inflammation and autoimmunity. Integrating psychodrama therapy to remediate stress alongside medical interventions marks a holistic approach to enhance patient well-being. The molecular underpinnings of vitiligo care are covered, emphasizing exciting advances revolutionizing vitiligo treatment and improving the quality of life for affected individuals.

biochemistry & molecular biology,cell biology,medicine, research & experimental
Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Wei-Ling Chang,Woan-Ruoh Lee,Yung-Che Kuo,Yen-Hua Huang

DOI: https://doi.org/10.3389/fcell.2021.797026

IF: 5.5

2021-12-14

Frontiers in Cell and Developmental Biology

Abstract:Vitiligo is a chronic autoimmune depigmenting skin disorder characterized by patches of the skin losing functional melanocytes. Multiple combinatorial factors are involved in disease development, among which immune T cells play a prominent role. The immune cells implicated in melanocyte destruction through adaptive immunity include CD8 + cytotoxic T cells and regulatory T cells, and aberrantly activated skin-resident memory T cells also play a role in melanocyte destruction. Over the past several years, major progress in understanding vitiligo pathogenesis has led to the development of targeted therapies. Janus kinase (JAK) inhibitors, which share the similar mechanism that autoactivates CD8 + T cells in chronic inflammatory diseases, have been reported to have therapeutic significance in vitiligo. Recently, immunomodulatory therapeutic interventions in vitiligo have been emerging. Mesenchymal stem cells (MSCs) regulate cytokine secretion and the balance of T-cell subsets, which makes them a promising cell-based treatment option for autoimmune diseases. The induction of MSC-mediated immunomodulation is complicated and occurs by contact-dependent mechanisms and soluble extracellular vesicle (EV) mediators. EVs released from MSCs contain various growth factors and cytokines with anti-inflammatory effects in the skin immune response. Here, we summarize and discuss the progress to date in targeted therapies that immunomodulate the niche environment of vitiligo, from the clinical trial of JAK inhibitors to the potential of MSCs and MSC-EVs. The available information was collected to highlight the need for further research into the treatment of vitiligo.

cell biology,developmental biology
Vitiligo: Translational research and effective therapeutic strategies

Vishal Thakur,Anuradha Bishnoi,Keshavamurthy Vinay,Sendhil M. Kumaran,Davinder Parsad

DOI: https://doi.org/10.1111/pcmr.12974

2021-04-05

Abstract:This is an exciting phase of vitiligo research with the current understanding of vitiligo pathogenesis and its translation to successful treatment. The pathogenetic origin of vitiligo revolves around autoimmunity with supporting role from many other factors like oxidative stress, inherent melanocyte defects or defective keratinocytes and fibroblasts.Vitiligo can be classified into segmental or non‐segmental depending upon the clinical presentation or it can be classified as progressing or stable based on the activity of the disease.Vitiligo treatments need to be stratified depending upon which type of vitiligo we are treating and at which phase the vitiligo patient presents to us.There are two different aims of treatment of vitiligo. The first involves rescuing the melanocytes from the damage to arrest the depigmentation. The second strategy focuses on replenishing the melanocytes so that successful repigmentation is achieved. It is also important to maintain the disease in a stable phase or prevent relapse. As stability in non‐segmental vitiligo is a dynamic process, maintenance of the stability of repigmentation is also an important consideration in the management of vitiligo. In this review, we shall briefly discuss the current options and future insight into the management of vitiligo

dermatology,oncology,cell biology
Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Yinghan Wang,Shuli Li,Chunying Li

DOI: https://doi.org/10.1007/s12016-021-08868-z

2021-07-20

Abstract:Vitiligo is an autoimmune disease of the skin characterized by epidermal melanocyte loss resulting in white patches, with an approximate prevalence of 0.5–2% worldwide. Several precipitating factors by chemical exposure and skin injury present commonly in patients with vitiligo. Although the diagnosis appears to be straightforward for the distinct clinical phenotype and specific histological features, vitiligo provides many challenges including chronicity, treatment resistance, frequent relapse, associated profound psychosocial effect, and negative impact on quality of life. Multiple mechanisms are involved in melanocyte disappearance, including genetics, environmental factors, and immune-mediated inflammation. Compelling evidence supports the melanocyte intrinsic abnormalities with poor adaptation to stressors leading to instability and release of danger signals, which will activate dendritic cells, natural killer cells, and innate lymphoid cells to initiate innate immunity, ultimately resulting in T-cell mediated adaptive immune response and melanocyte destruction. Importantly, the cross- talk between keratinocytes, melanocytes, and immune cells, such as interferon (IFN)-γ signaling pathway, builds inflammatory loops that give rise to the disease deterioration. Improved understanding of the immune pathogenesis of vitiligo has led to the development of new therapeutic options including Janus kinase (JAK) inhibitors targeting IFN-γ signaling pathways, which can effectively reverse depigmentation. Furthermore, definition of treatment goals and integration of comorbid diseases into vitiligo management have revolutionized the way vitiligo is treated. In this review, we highlight recent developments in vitiligo clinical aspects and immune pathogenesis. Our key objective is to raise awareness of the complexity of this disease, the potential of prospective therapy strategies, and the need for early and comprehensive management.

immunology,allergy
Advances in vitiligo: Update on therapeutic targets

Yifei Feng,Yan Lu

DOI: https://doi.org/10.3389/fimmu.2022.986918

IF: 7.3

2022-08-31

Frontiers in Immunology

Abstract:Vitiligo, whose treatment remains a serious concern and challenge, is an autoimmune skin disease characterized by patches of depigmentation. The increasing application of molecular-targeted therapy in skin diseases, such as psoriasis and systemic lupus erythematosus, has dramatically improved their condition. Besides, there is a favorable effect of repigmentation in the treatment of the above diseases combined with vitiligo, implying that molecular-targeted therapy may also have utility in vitiligo treatment. Recently, the role of cytokine and signaling pathways in vitiligo pathogenesis are increasingly recognized. Thus, investigations are underway targeting the molecules described above. In this paper, we present a synopsis of current practices in vitiligo treatment and introduce the improvement in identifying new molecular targets and applying molecular-targeted therapies, including those under development in vitiligo treatment, providing valuable insight into establishing further precision medicine for vitiligo patients.

immunology
Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments

Shahriar Ghashghaei,Mahkameh Abbaszadeh,Shahedeh Karimi,Leila Ataie-Fashtami,Amir Bajouri,Massoud Vosough

DOI: https://doi.org/10.22074/cellj.2023.557550.1067

2023-03-07

Abstract:Vitiligo is an auto-immune disease, causing depigmentation of skin in 0.2-1.8% of global population. Topical corticosteroids and calcineurin inhibitors are the only treatments with firm evidence of optimal effectiveness with considerable side effects. Phototherapies might not induce serious side effects, although the effectiveness of the method is limited. Advanced therapy medicinal products (ATMPs) are emerging treatment modalities based on correction and replacement of affected genes, damaged tissues or cells in treatment of difficult-to-treat diseases. Due to optimal effectiveness and minimal side effects, ATMPs have recently gained much attention in order to develop new treatments. In this review, the ATMPs for treating vitiligo were along with its clinical success, affordability and cost-effectiveness. Currently, the main ATMP based products using in treatment of vitiligo are non-cultured epidermal cell, melanocytes, and hair follicle melanocytes. These products have shown promising results in the non-responding vitiligo patients. Furthermore, mesenchymal stem cells and multi-lineage differentiating stress enduring cells are other new potential modalities. Recently, Iranian Food and Drug Administration (IR-FDA) authorized the first cell-based product for vitiligo. This product is autologous suspension of keratinocytes and melanocytes. Although ATMPs are efficient and could be cost-effective in long term, the most important obstacle is affordability of them. This could be facilitated by insurance companies and instalments payment programs from manufacturers.
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Katia Boniface,Julien Seneschal,Mauro Picardo,Alain Taïeb

DOI: https://doi.org/10.1007/s12016-017-8622-7

2017-07-06

Abstract:Vitiligo is an acquired chronic depigmenting disorder of the skin, with an estimated prevalence of 0.5% of the general population, characterized by the development of white macules resulting from a loss of epidermal melanocytes. The nomenclature has been revised after an extensive international work within the vitiligo global issues consensus conference, and vitiligo (formerly non-segmental vitiligo) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses. The auto-immune/inflammatory theory is the leading hypothesis because (1) vitiligo is often associated with autoimmune diseases; (2) most vitiligo susceptibility loci identified through genome-wide association studies encode immunomodulatory proteins; and (3) prominent immune cell infiltrates are found in the perilesional margin of actively depigmenting skin. However, other studies support melanocyte intrinsic abnormalities with poor adaptation of melanocytes to stressors leading to melanocyte instability in the basal layer, and release of danger signals important for the activation of the immune system. Recent progress in the understanding of immune pathomechanisms opens interesting perspectives for innovative treatment strategies. The proof of concept in humans of targeting of the IFNγ /Th1 pathway is much awaited. The interplay between oxidative stress and altered immune responses suggests that additional strategies aiming at limiting type I interferon activation pathway as background stabilizing therapies could be an interesting approach in vitiligo. This review covers classification and clinical aspects, pathophysiology with emphasis on immunopathogenesis, and promising therapeutic approaches.

immunology,allergy
Future needs--diagnostic services.

M. Nicolas-Chanoine

DOI: https://doi.org/10.1046/J.1469-0691.2000.00127.X

IF: 13.31

2000-08-01

Clinical Microbiology and Infection

Abstract:
Updates and new medical treatments for vitiligo (Review)

David Emmanuel Kubelis-López,Natalia Aranza Zapata-Salazar,Salvador Luis Said-Fernández,Celia Nohemí Sánchez-Domínguez,Mauricio Andrés Salinas-Santander,Herminia Guadalupe Martínez-Rodríguez,Osvaldo Tomás Vázquez-Martínez,Uwe Wollina,Torello Lotti,Jorge Ocampo-Candiani,David Kubelis‑López,Natalia Zapata‑Salazar,Salvador Said‑Fernández,Celia Sánchez‑Domínguez,Mauricio Salinas‑Santander,Herminia Martínez‑Rodríguez,Osvaldo Vázquez‑Martínez,Jorge Ocampo‑candiani

DOI: https://doi.org/10.3892/etm.2021.10229

IF: 2.7

2021-05-25

Experimental and Therapeutic Medicine

Abstract:Vitiligo is a multifactorial disease characterized by the loss of skin pigment, which results in achromic macules and patches. There are currently several medical treatments available, which aim to arrest progression and induce skin repigmentation. These treatments alone or combined have exhibited varying degrees of pigmentation, and the majority are safe and effective. All therapies for vitiligo are limited, and no known treatment can consistently produce repigmentation in all patients. Individualized treatment is appropriate according to the location, clinical presentation and the presence of disease activity. The present review summarizes the medical treatments available for vitiligo: Systemic and topic pharmacological therapies, physical and depigmentation treatments. Several treatments are still underway and have not yet been approved. However, due to the promising preliminary results, these are also mentioned in the present review.

medicine, research & experimental
The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo

David Bitterman,Margaret Kabakova,Jennifer Y. Wang,Alexia Collins,Paras Patel,Neal Gupta,Kayla Zafar,Marc Cohen,Jared Jagdeo

DOI: https://doi.org/10.1007/s00403-024-03405-2

2024-10-07

Archives of Dermatological Research

Abstract:Vitiligo is a chronic autoimmune disorder characterized by progressive skin depigmentation. Vitiligo significantly impacts patients' quality of life, contributing to psychological and social burdens. Despite readily available therapeutic options, many cases remain refractory to treatment, highlighting the critical need for safer and more effective therapies. Currently, ruxolitinib is the only FDA-approved medication for vitiligo; however, it carries a black box warning for serious adverse effects, including infections, malignancy, and major cardiovascular events, limiting its use. Recent studies have identified the aryl hydrocarbon receptor (AhR) as a promising therapeutic target, suggesting that AhR agonists could address the multifaceted pathogenesis of vitiligo. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive search to analyze the role of AhR agonists in the treatment of vitiligo on PubMed, Cochrane, Embase, MEDLINE, and Web of Science databases on April 15, 2024. Fourteen studies met the inclusion criteria, comprising two clinical trials, two case reports, and nine basic science studies. Our search revealed that culturing AhR agonists with melanocytes upregulates melanin-synthesizing enzymes, reduces reactive oxygen species, and modulates pro-inflammatory cytokines such as IL-17A and IL-22. Tapinarof, a topical AhR agonist used commonly for the treatment of psoriasis, demonstrated clinical efficacy in repigmentation with a favorable safety profile compared to long-term steroid use. Although limited by the number of clinical studies, this review underscores the potential of using AhR agonists, such as tapinarof, as a transformative approach to vitiligo management. Future clinical trials are necessary to evaluate the safety, efficacy, and long-term outcomes of AhR agonists.

dermatology
The biomechanics of the Syme prosthesis.

C. W. Radcliffe

1961-04-01

Abstract:
Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Torello Lotti,Jana Hercogova,Giuseppe Fabrizi

DOI: https://doi.org/10.1517/14656566.2015.1087508

2015-09-15

Expert Opinion on Pharmacotherapy

Abstract:INTRODUCTION: Vitiligo is a skin disorder characterized by a progressive depigmentation, which is caused by the loss of melanocytes at the cutaneous level. A shift of the immune system with a prevalence of T helper (Th)1/Th17 response instead of a Tregs/Th2 one and may be part of etiology of 10 vitiligo.AREAS COVERED: This review describes the major points of vitiligo onset and shows the cutting-edge results in the field of low-dose medicine in the treatment of dermatologic diseases and, in particular. in vitiligo. In this review on advances in vitiligo pharmacotherapy, the most pertinent recent publications are reported. Electronic databases such as PubMed were searched for terms 'low-dose medicine' or 'low dose and vitiligo' or 'low dose and psoriasis.'EXPERT OPINION: The availability of a systemic treatment for vitiligo, based on the oral administration of low-dose activated signaling molecules represents an opportunity for the dermatologists to overcome some specific pitfalls of currently available therapeutic protocols.

pharmacology & pharmacy
Current and emerging treatments for vitiligo

Michelle Rodrigues,Khaled Ezzedine,Iltefat Hamzavi,Amit G. Pandya,John E. Harris,Vitiligo Working Group

DOI: https://doi.org/10.1016/j.jaad.2016.11.010

IF: 15.487

2017-07-01

Journal of the American Academy of Dermatology

Abstract:Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are safe and effective treatments available for vitiligo. It is important to recognize common and uncommon presentations and those with active disease, as well as their implications for clinical management; these were discussed in the first article in this continuing medical education series. Existing treatments include topical and systemic immunosuppressants, phototherapy, and surgical techniques, which together may serve to halt disease progression, stabilize depigmented lesions, and encourage repigmentation. We discuss how to optimize the currently available treatments and highlight emerging treatments that may improve treatment efficacy in the future.

dermatology
[Therapy of patients of cerebral motor disorders].

G. Tardieu

1958-06-01

Abstract:
Management of the refractory vitiligo patient: current therapeutic strategies and future options

Xinju Wang,Wei Wu,Jianru Chen,Chunying Li,Shuli Li

DOI: https://doi.org/10.3389/fimmu.2023.1294919

IF: 7.3

2024-01-05

Frontiers in Immunology

Abstract:Vitiligo is an autoimmune disease that leads to disfiguring depigmented lesions of skin and mucosa. Although effective treatments are available for vitiligo, there are still some patients with poor responses to conventional treatment. Refractory vitiligo lesions are mostly located on exposed sites such as acral sites and lips, leading to significant life stress. Understanding the causes of refractory vitiligo and developing targeted treatments are essential to enhance vitiligo outcomes. In this review, we summarized recent treatment approaches and some potential methods for refractory vitiligo. Janus kinase inhibitors have shown efficacy in refractory vitiligo. A variety of surgical interventions and fractional carbon dioxide laser have been widely applied to combination therapies. Furthermore, melanocyte regeneration and activation therapies are potentially effective strategies. Patients with refractory vitiligo should be referred to psychological monitoring and interventions to reduce the potential pathogenic effects of chronic stress. Finally, methods for depigmentation and camouflage may be beneficial in achieving uniform skin color and improved quality of life. Our ultimate focus is to provide alternative options for refractory vitiligo and to bring inspiration to future research.

immunology
Vitiligo: A focus on pathogenesis and its therapeutic implications

Christina Bergqvist,Khaled Ezzedine

DOI: https://doi.org/10.1111/1346-8138.15743

IF: 3.468

2021-01-06

The Journal of Dermatology

Abstract:Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population worldwide. The characteristic white patches result from the selective loss of melanocytes. Sustained recent efforts have resulted in a detailed understanding of the genetic architecture of vitiligo. About 80% of vitiligo risk is attributable to genetic factors; and the rest (20%) is attributable to the environment. Over the past decade, substantial progress has been made in our understanding of the pathogenesis of vitiligo which is now clearly classified as an autoimmune disease. Melanocytes from patients with vitiligo are more susceptible to oxidative stress which begets the release of exosomes and inflammatory cytokines that will lead to activation of the innate immune response and subsequently to adaptive immune response through activation of autoreactive cytotoxic CD8+ T cells. These produce interferon‐γ (IFN‐γ) which promotes disease progression through IFN‐γ‐induced chemokine secretion from surrounding keratinocytes to further recruit T cells to the skin through a positive feedback loop. CD8 tissue‐resident memory T cells are in turn responsible for long‐term maintenance and potential relapse of vitiligo in human patients through cytokine‐mediated recruitment of T cells from the circulation. This review summarizes the current knowledge on vitiligo and attempt to give an overview of the future in vitiligo treatment.
Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences

Priti Paul,Harithasree Veerabomma,Ujala Gupta,Divya Atram,Pankaj Kumar Singh,Neelesh Kumar Mehra,Chandraiah Godugu,Ashish Baldi,Jitender Madan

DOI: https://doi.org/10.1016/j.jddst.2024.105666

IF: 5

2024-04-28

Journal of Drug Delivery Science and Technology

Abstract:Vitiligo is an autoimmune disease that spreads depigmented patches on the skin and has a negative impact on a patient's mental health, physical health, and quality of life. It is a multifaceted disorder that involves both genetic predisposition and environmental triggers. Non-segmental vitiligo, segmental vitiligo, and unclassified vitiligo are the three major subtypes of vitiligo. The pathophysiology of vitiligo is complex and involves multiple combinatorial factors. Research development has identified oxidative stress, autoimmune illness, and auto-inflammation as major contributors to vitiligo. The complexity of vitiligo's pathogenesis makes its treatment challenging. Vitiligo treatment has three primary goals prevention of the spread of depigmentation, promotion of repigmentation, and reduction of psychological distress. Current therapeutic strategies include non-targeted and broad immunosuppressants that only partially relieve symptoms without changing the natural course of the disease. Vitiligo management aims to reduce disease progression, stimulate repigmentation, and prevent relapses. Statins inhibit IFN-γ and ROS production. JAK-STAT inhibitors block IFN-γ signaling and support the repigmentation of vitiligo and Topical prostaglandin analogs stimulate the growth of melanocytes. Topical colloidal therapeutics exploited the properties of the stratum corneum to improve transdermal drug delivery and their therapeutic effects. This review aims at the pathophysiology, cellular signaling mechanism, emerging drug targets and topical drug delivery strategies in treating vitiligo. This research achieved substantial progress by enhancing drug penetration or drug loading efficiency. Graphical abstract Download : Download high-res image (353KB) Download : Download full-size image

pharmacology & pharmacy
A view of dataflow*

K. Gostelow,Robert E. Thomas

DOI: https://doi.org/10.1109/MARK.1979.8817119

1979-06-01

Abstract:In 1946 John von Neumann outlined an organization for computers 1 that has dominated the languages and architecture of machines to this day—the familiar sequential, one-word-at-a-time instruction stream which modifies the contents of a memory. Although the von Neumann model has proved to be a viable and powerful approach to computation, we have chosen to explore other models of computation to determine if they offer advantages in ease of programming, exploitation of concurrency and performance. A primary motivation is new technology such as large scale integration (LSI) which has greatly expanded the range of choice in computer design.
Vitiligo nonsurgical treatment: a review of latest treatment researches

Yanfei Zhang,Jessini Soranambal Mooneyan‐Ramchurn,Nan Zuo,Yiguo Feng,Shengxiang Xiao,Jessini Soranambal Mooneyan-Ramchurn

DOI: https://doi.org/10.1111/dth.12143

2014-07-12

Dermatologic Therapy

Abstract:Vitiligo is a common depigmenting acquired disorder affecting about 1-2% of the world population, regardless of race, ethnic background, or gender. It is characterized by the appearance of milky white maculae because of a loss of melanocytes. The disfiguring nature of vitiligo causes high psychosocial morbidity. This is especially pronounced in populations with darker skin tone, likely because of the marked contrast. A variety of nonsurgical treatment regimens are currently employed in vitiligo. We reviewed the latest studies carried out on different nonsurgical treatment modalities used in vitiligo. All nonsurgical treatment aid to repigment or depigmentation the skin, however, many of them require a prolonged treatment course and may yield minimal results as well as carry unwanted side effects. There is a need for further research into the causes of vitiligo and into discovering better treatments.

dermatology

José M. Seco, Emilio Quiñoá, and Ricardo Riguera: The assignment of the absolute configuration by NMR using chiral derivatizing agents: a practical guide

Emerging drugs for the treatment of vitiligo

Vitiligo: advances in pathophysiology research and treatment development

Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention

Vitiligo: Translational research and effective therapeutic strategies

Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo

Advances in vitiligo: Update on therapeutic targets

Advanced Therapy Medicinal Products in Vitiligo; Current Status, Future Prospect, and Approved Treatments

Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Future needs--diagnostic services.

Updates and new medical treatments for vitiligo (Review)

The role of aryl hydrocarbon receptor agonists in the treatment of vitiligo

The biomechanics of the Syme prosthesis.

Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy

Current and emerging treatments for vitiligo

[Therapy of patients of cerebral motor disorders].

Management of the refractory vitiligo patient: current therapeutic strategies and future options

Vitiligo: A focus on pathogenesis and its therapeutic implications

Implication of colloidal therapeutics in the treatment of vitiligo: Portray of signaling cascade, current drug-targets and preclinical and clinical evidences

A view of dataflow*

Vitiligo nonsurgical treatment: a review of latest treatment researches